Last reviewed · How we verify

NCT05939401: ANCABio

A Study Regarding Tissue Response During and After Treatment for Anal Cancer

Recruiting now Last updated 18 March 2025
What this trial tests

trial testing Biopsies in Anal Cancer in 400 participants. Currently enrolling.

Timeline
1 December 2023
Primary endpoint
1 December 2027
1 December 2029

Quick facts

Lead sponsorSahlgrenska University Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment400
Start date1 December 2023
Primary completion1 December 2027
Estimated completion1 December 2029
Sites2 locations across Sweden

Drugs / interventions tested

Conditions studied

Sponsor

Sahlgrenska University Hospital

Who can join

18 and older, any sex, with Anal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to improve the understanding for the tumour biology in relation to treatment response in patients with anal cancer by examining: * The tumour microenvironment * The localisation of and cellular interactions between the tumour and immune cells * The gene and protein expression by cells present in the tumour and surrounding tissue.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Biopsies

Trials testing the same drug.

Other recruiting trials for Anal Cancer

Currently open trials in the same condition.

Other Sahlgrenska University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05939401.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing